Cboe Europe Technology Sector PR/ DE000SLA3EX1
BEPTEC11.06.2024 13:29:18 | Изменение -253.46 | Открыть | Максимум | Минимум | Предыдущее закрытие |
---|---|---|---|---|---|
51,836.07XXP | -0.49% | 52,089.53 | 52,318.71 | 51,769.14 | 52,089.53 |
GlobeNewswire
13:18
MRNS Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Clas...
GlobeNewswire
13:15
AppTech Payments Announces Strategic Partnership with FISB Solutions to Upgrade Legacy Banking Syste...
GlobeNewswire
13:05
Kraig Biocraft Laboratories Announces Production Update for BAM-1 Spider Silk Hybrids
GlobeNewswire
13:05
Banks are making climate commitments, but are they actually making a difference?
GlobeNewswire
13:03
New Report From Meltwater and Asana Reveals Disconnect Between Marketing Goals and Business Objectiv...
GlobeNewswire
13:00
Lithium Ionic Completes Acquisition of Remaining 15% of Salinas Properties, Minas Gerais, Brazil
GlobeNewswire
13:00
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
13:00
Simply Good Foods to Report Third Quarter Fiscal Year 2024 Financial Results on Thursday, June 27, 2...
GlobeNewswire
13:00
Republic enhances tokenized asset accessibility with Zero Hash's fiat and USDC payment rails
GlobeNewswire
13:00
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule ...
GlobeNewswire
13:00
Almaden to Pursue International Arbitration Against Mexico; Moves to Drop Mexican Lawsuits
GlobeNewswire
13:00
PyroGenesis Signs Contracts Totaling $2.5 Million to Deliver Greenhouse Gas-Reducing System for Majo...
GlobeNewswire
13:00
ZeroFox Named Winner of the Global InfoSec Awards and Cybersecurity Excellence Awards
GlobeNewswire
13:00
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patie...
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница